Skip to main content

Table 1 Baseline demographics and patient characteristics

From: Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain

Characteristic Tapentadol prolonged Oxycodone controlled
release (n = 978) release (n = 999)
Mean ± SD age, years 56.8 ± 12.22 56.7 ± 12.39
Age category, n (%):   
<65 years 719 (73.5) 731 (73.2)
≥65 years 259 (26.5) 268 (26.8)
Gender, n (%)   
   Female 639 (65.3) 601 (60.2%)
   Male 339 (34.7) 398 (39.8)
Race, n (%)   
   White 803 (82.1) 813 (81.4)
   Black 111 (11.3) 101 (10.1)
   Hispanic 40 (4.1) 58 (5.8)
   Other 24 (2.5) 27 (2.7)
Pain condition, n (%)   
   Osteoarthritis knee pain 663 (67.8) 673 (67.4)
   Low back pain 315 (32.2) 326 (32.6)
   Mean ± SD pain intensity score *+ 7.4 ± 1.26 7.3 ± 1.21
Pain intensity category, n (%) + ~   
   Mild 2 (0.2) 0
   Moderate 119 (12.2) 123 (12.3)
   Severe 854 (87.6) 873 (87.7)
Prior opioid experience, n (%)   
   No 641 (65.5) 681 (68.2)
   Yes 337 (34.5) 318 (31.8)
  1. *Average pain score (11 point numerical rating scale) recorded over the last 72 hours prior to randomisation.
  2. + Tapentadol n = 975, oxycodone n = 996.
  3. ~ Mild pain intensity defined as 1 to <4 on the numerical rating scale, moderate >4 to <6 and severe ≥6.